Navigation Links
Serial Monitoring With ImmuKnow(R) is Useful in the Risk Assessment of Kidney Transplant Recipients
Date:5/30/2009

The results of this study will be presented during the American Transplant Congress in Boston, MA May 30 - June 3, 2009

COLUMBIA, Md., May 30 /PRNewswire/ -- Lead investigator, Dr. Manuel R. Carreno, along with his colleagues from the University of Miami, evaluated whether single or serial ImmuKnow assessments are most useful in determining rejection or infection in kidney transplant recipients. Patients were randomly selected after 30-60 days (N=134) or 335-395 days posttransplant (N=91) and tested with ImmuKnow.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090424/NE99362LOGO )

Based on the results of this study, Dr. Carreno commented, "Pre-transplant baseline readings and serial monitoring with ImmuKnow are crucial for posttransplant risk assessments. Our results suggest that an isolated ImmuKnow test is insufficient to aid in the management of posttransplant recipients." In addition, Dr. Carreno said, "Serial posttransplant ImmuKnow values are useful because patients with 'immunological quiescence' have fewer complications compared to patients with erratic ImmuKnow values."

"We believe that ImmuKnow is a valuable, noninvasive tool for helping clinicians manage their transplant patients," added Dr. Phillip Ruiz, author and Medical Director of the Transplant Laboratories. "We recognize that the immune system responds quickly to change and that regular patient monitoring is critical to understanding these changes, which is why we test weekly in the first month posttransplant, followed by weeks 6 and 8 testing in the second month, monthly testing during months 3-12, and then as needed when circumstances suggest the immune function is affected."

Risk assessment was performed within 3 study groups: The first group utilized single ImmuKnow measures alone, the second group compared posttransplant vs. pre-transplant ImmuKnow results and the third group compared posttransplant ImmuKnow results with other prior serial posttransplant ImmuKnow results taken during immunological quiescence.

The use of the ImmuKnow assay as described in this study has not been cleared by the U.S. Food & Drug Administration.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of the ImmuKnow assay should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.

About Cylex, Inc.

Cylex is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products that are intended to illuminate immunity. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides an innovative platform allowing clinicians to simply and reproducibly assess CMI. The Company is based in Columbia, MD USA.

http://www.cylex.net


'/>"/>
SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
4. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
5. Oridion Launches its Fully Integrated Remote Monitoring System and SARA Software for Improved Patient Safety
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
9. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
11. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... ... 11, 2017 , ... Disappearing forests and increased emissions are the main causes ... each year. Especially those living in larger cities are affected by air pollution related ... the most pollution-affected countries globally - decided to take action. , “I knew I ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second time in ... STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, ... , US2020’s mission is to change the trajectory of STEM education in America ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):